Artiva Biotherapeutics, Inc. (ARTV)
NASDAQ: ARTV · Real-Time Price · USD
3.990
+0.140 (3.64%)
At close: Feb 12, 2026, 4:00 PM EST
3.940
-0.050 (-1.25%)
After-hours: Feb 12, 2026, 5:26 PM EST
Artiva Biotherapeutics Employees
Artiva Biotherapeutics had 106 employees as of September 30, 2025. The number of employees increased by 24 or 29.27% compared to the same quarter last year.
Employees
106
Change
24
Growth
29.27%
Revenue / Employee
n/a
Profits / Employee
-$747,057
Market Cap
97.93M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Sep 30, 2025 | 106 | 24 | 29.27% |
| Jun 30, 2025 | 105 | 23 | 28.05% |
| Mar 31, 2025 | 96 | 15 | 18.52% |
| Dec 31, 2024 | 89 | 8 | 9.88% |
| Sep 30, 2024 | 82 | - | - |
| Jun 30, 2024 | 82 | - | - |
| Mar 31, 2024 | 81 | - | - |
| Dec 31, 2021 | 43 | 21 | 95.45% |
| Dec 31, 2020 | 22 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Seer, Inc. | 134 |
| Immunic | 90 |
| Verrica Pharmaceuticals | 71 |
| Biomea Fusion | 42 |
| Vivani Medical | 37 |
| Equillium | 35 |
| Oncolytics Biotech | 28 |
| Cognition Therapeutics | 28 |
ARTV News
- 22 days ago - Artiva Biotherapeutics Announces Upcoming Presentations at the 2026 Transplantation & Cellular Therapy Meetings of ASTCT® and CIBMTR® (Tandem Meetings) Highlighting Cost-Effectiveness of AlloNK in a Community Rheumatology Practice and Continued Durability of AlloNK in NHL - GlobeNewsWire
- 27 days ago - Artiva Biotherapeutics: Upcoming Data Presentations May Bring Them Out Of Being Ignored - Seeking Alpha
- 3 months ago - Artiva Biotherapeutics Announces Positive Initial Safety and Translational Data Supporting Deep B-Cell Depletion with AlloNK® in Autoimmune Disease - GlobeNewsWire
- 3 months ago - Artiva Biotherapeutics Reports Third Quarter 2025 Financial Results and Recent Business Highlights - GlobeNewsWire
- 3 months ago - Artiva Biotherapeutics to Host Virtual Event Discussing Initial Safety and Translational Data in up to 32 Patients with Autoimmune Disease Treated with AlloNK® - GlobeNewsWire
- 3 months ago - Artiva Biotherapeutics to Participate in Upcoming Investor Conferences in November - GlobeNewsWire
- 4 months ago - Artiva Biotherapeutics Announces Refractory Rheumatoid Arthritis as Lead Indication, Upcoming Data Releases, and Corporate Update - GlobeNewsWire
- 6 months ago - Artiva Biotherapeutics to Participate in the Cantor Global Healthcare Conference 2025 - GlobeNewsWire